Market closed

NovoCure/$NVCR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Ticker

$NVCR
Trading on

Industry

Health Care Equipment & Supplies

Headquarters

Saint Helier, Jersey

Employees

1,453

NovoCure Metrics

BasicAdvanced
$3.2B
Market cap
-
P/E ratio
-$1.39
EPS
0.70
Beta
-
Dividend rate
$3.2B
0.7
$29.05
$11.66
1.5M
1.49
1.432
32.788
187.268
-17.55%
-7.93%
-39.70%
5.529
8.9
8.9
-40.845
14.63%
-25.18%
1.92%
73.31%

What the Analysts think about NovoCure

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for NovoCure stock.

NovoCure Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NovoCure Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVCR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for NovoCure stock?

NovoCure (NVCR) has a market cap of $3.2B as of December 11, 2024.

What is the P/E ratio for NovoCure stock?

The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of December 11, 2024.

Does NovoCure stock pay dividends?

No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of December 11, 2024.

When is the next NovoCure dividend payment date?

NovoCure (NVCR) stock does not pay dividends to its shareholders.

What is the beta indicator for NovoCure?

NovoCure (NVCR) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.